A

Acumen Pharmaceuticals, Inc. (ABOS)

NMS – Real vaqt narxi. Valyuta: USD

2.48

-0.09 (-3.50%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

A

Acumen Pharmaceuticals, Inc. (ABOS)

NMS – Real vaqt narxi. Valyuta: USD

2.48

-0.09 (-3.50%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript

12.05.2026

Acumen Pharmaceuticals Q1 Earnings Call Highlights

Acumen Pharmaceuticals NASDAQ: ABOS said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results expected late in 2026, as the company continues to advance its broader Alzheimer's disease pipeline.

12.05.2026

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2026 and provided a business update.

07.05.2026

Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on Thursday, May 14, 2026, at 8:55 a.m.

05.05.2026

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter financial results on Tuesday, May 12, 2026.

31.03.2026

Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

30.03.2026

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2026 and provided a business update.

07.05.2026

Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on Thursday, May 14, 2026, at 8:55 a.m.

26.03.2026

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the full year ended December 31, 2025 and provided a business update.

16.03.2026

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

NEWTON, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 million of shares of its common stock at a price of $3.30 per share. Acumen expects to receive gross proceeds from the offering of approximately $35.75 million, before deducting offering expenses.

Search stocks

Acumen Pharmaceuticals, Inc. (ABOS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Acumen Pharmaceuticals, Inc. (ABOS)

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript

Acumen Pharmaceuticals Q1 Earnings Call Highlights

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?

Videolar

No Data

Press-relizlar

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio